Zacks Research Has Bearish Estimate for PBH Q2 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Tuesday, January 14th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.18 per share for the quarter, down from their previous forecast of $1.19. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2026 earnings at $1.24 EPS and Q3 2027 earnings at $1.30 EPS.

Several other research firms have also commented on PBH. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research report on Monday, December 9th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reiterated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, StockNews.com downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $85.25.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $78.58 on Friday. The company’s fifty day simple moving average is $80.52 and its 200-day simple moving average is $74.49. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare has a 52 week low of $58.22 and a 52 week high of $86.36. The company has a market cap of $3.88 billion, a PE ratio of 19.12, a P/E/G ratio of 2.08 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same quarter last year, the firm posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 in the last 90 days. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ariel Investments LLC lifted its holdings in Prestige Consumer Healthcare by 10.7% during the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after buying an additional 274,212 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Prestige Consumer Healthcare by 19.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after purchasing an additional 255,045 shares during the last quarter. Geode Capital Management LLC lifted its stake in Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Congress Asset Management Co. boosted its holdings in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock worth $62,375,000 after purchasing an additional 62,411 shares during the period. Finally, Boston Trust Walden Corp bought a new stake in Prestige Consumer Healthcare during the third quarter valued at $41,785,000. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.